Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

apies, Inc. ("Shire"), is engaged in ongoing discussions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMEA) and will provide an update by the end of the year. A final decision on the global development strategy will follow the conclusion of the discussions with both agencies. Subject to the outcome of the discussions, the Company expects to initiate Phase 3 development of Amigal in the first half of 2009.

In addition, 23 of the original 26 patients continue to be treated in a voluntary Phase 2 extension study designed to monitor long-term safety and efficacy and to evaluate additional doses and dose regimens. Data from this extension study are expected in Q1 2009 prior to the start of the Phase 3 study.

Gaucher Disease:

Plicera(TM) (isofagomine tartrate) is an investigational, oral therapeutic in Phase 2 development for the treatment of Gaucher disease. As previously disclosed, a 6-month Phase 2 clinical trial of Plicera in patients naive to ERT is ongoing and Amicus expects the results of this study to be available in 2009.

Pompe Disease:

AT2220 (1-deoxynojirimycin HCl) is an investigational, oral therapeutic being developed for the treatment of Pompe disease. As previously disclosed, a Phase 2 clinical trial of AT2220 in adult Pompe patients is ongoing and includes an 11 week treatment period with an optional extension study.

In addition, Amicus is conducting preclinical animal studies to evaluate the effects of administering AT2220 in combination with enzyme replacement therapy. Based on the results of the preclinical work, Amicus will consider initiating a clinical trial of the AT2220-ERT combination treatment in Pompe patients.

Other Chaperone Programs:

Amicus continues to invest in research and development to assess the potential for using pharmacological chaperones to treat a broader range of human genetic diseases beyond lysosomal storage diseases. As part of this
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... October 19, 2014 The Asian Automatic ... Asian with analysis and forecast of revenue. The Automatic ... to around $463.9 million by 2018, at a developing ... through the TOC of the Asian Automatic patient billing ... provided. This also provides a glimpse of the segmentation ...
(Date:10/19/2014)... October 19, 2014 The report "Chocolate, ... Share, Trade, Prices, Geography Trend and Forecast (2011 - ... category, and geography and studies the major market drivers, ... America, Europe, and Asia. , The global chocolate market ... $98.3 billion in 2016 at an estimated CAGR of ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 The ... Defense, & Homeland Security), Technology, Payload, Type & ... and segments the global unmanned ground vehicle market ... and forecasting of market sizes. The report also ... and opportunities impacting it along with the adoption ...
(Date:10/18/2014)... The “Human Insulin Market- by Product Type, [Human ... Insulin (Rapid Acting, Long Acting, Premixed)], by Brand ... Forecast to 2018” provides a detailed overview of ... trends, and strategies impacting the global human insulin ... the revenue and share analysis. , The global ...
Breaking Biology Technology:The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 2Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 3Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 4Unmanned Ground Vehicle (UGV) Market Estimated to Reach $8.26 Billion by 2020 - New Research Report by MarketsandMarkets 5Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5
... , ... , , , , ... 2100 bioanalyzer can,be used in combination with Standardized RT (StaRT)-PCR ... obtain highly reproducible, standardized gene expression,measurement with RT-PCR. The internal ...
... , , ... , , , This Application ... kit can be used to detect cell surface,and intracellular protein targets ... staining on CCRF-CEM cells and intracellular,glucocorticoid receptor (GR) staining of H4 ...
... , ... , , This Application Note describes ... be used to determine the efficiency,of transfection of mammalian cells using ... with,expression vectors encoding GFP from two different sources, and optimization,of transfection ...
Cached Biology Technology:Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 2Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 3Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 4Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 5Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 6Quantitative end-point RT-PCR gene,expression measurement using the,Agilent 2100 Bioanalyzer and,standardized RT-PCR 7Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 2Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 3Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 4Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 5Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 6Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 7Detection of antibody-stained cell,surface and intracellular protein targets,with the Agilent 2100 bioanalyzer 8Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 2Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 3Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 4Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 5Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 6Monitoring transfection efficiency by,green fluorescent protein (GFP) detection,with the Agilent 2100 bioanalyzer 7
(Date:10/15/2014)... virus is spreading rapidly and to an unexpected extent. ... the past and the virus shows a new disease ... before. For this reason, the German National Academy of ... and Engineering, and the Union of the German Academies ... the Ebola epidemic today. , In the statement the ...
(Date:10/14/2014)... Like discriminating thieves, prostate cancer tumors scavenge and hoard ... But such avarice may be a fatal weakness. ... to kill prostate cancer cells by delivering a trove ... the diseased cells brimming with the mineral, leaving non-cancer ... drugs already commercially available for other uses, could soon ...
(Date:10/14/2014)... research team has discovered a new kind of stem cell ... that lines liver blood vessels, according to a study published ... existence of such a cell type contradicts current theory on ... may hold clues to origins of, and future treatment for, ... single cell into a complex being made up of more ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 2Stem cell discovery challenges dogma on how fetus develops; holds insights for liver cancer and reg 3
... scientists at the University of Minnesota Medical School and ... and made suggestions on how to advance research and ... published in the January 2008 issue of the Lancet ... , Many neurological disorders are difficult to treat because ...
... and the National Center for Ecological Analysis and Synthesis ... predict gene flow across landscapes. Their approach could give ... for wildlife corridors, which are crucial to protecting biodiversity. ... theory and ecological connectivity, said Brad McRae, head of ...
... the University of California, San Diego have discovered a ... in the gene are present in both the female ... a paper that appears online today in the journal ... consent mutation because of its unusual properties. Mutations ...
Cached Biology News:International scientists tackle obstacles to treating brain disorders 2International scientists tackle obstacles to treating brain disorders 3Model connects circuit theory to wildlife corridors 2Biologists find unusual plant gene: abstinence by mutual consent 2Biologists find unusual plant gene: abstinence by mutual consent 3
... Error-free cloning of BAC (100+kb), fosmid ... Greater insert stability than any othe BAC ... for high yields and easy recombinant DNA ... or transcription-free (pSMART VC) vectors for the ...
Anti-Goat HRP-DAB Cell & Tissue Staining Kit...
CHIMAERIC HUMAN IgA2 ANTI NP...
... Cloning Kit includes the pZErO-2 ... selection in E. coli. The ... to eliminate high background. The ... reagents you need for simple ...
Biology Products: